Brief: Clarity Receives Us FDA Fast Track Designation For The Treatment Of Metastatic Castration-Resistant Prostate Cancer Patients With Cu-67 Sar-Bispsma
19/02/2025 15:12
Feb 19 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* CLARITY RECEIVES US FDA FAST TRACK DESIGNATION FOR THE
TREATMENT
OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH
CU-67 SAR-BISPSMA
Source text: ID:nPn29BQ1sa
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial